U. Karey

Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity

G. Colucci, S. Zeuzem, C. Sarrazin, 2011, Journal of Clinical Microbiology.

HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a

Tara L. Kieffer, A. Kwong, E. Herrmann, 2011, Scandinavian journal of gastroenterology.

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b

X. Tong, R. Ralston, S. Zeuzem, 2012, Journal of viral hepatitis.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

F. S. Domingues, X. Tong, R. Ralston, 2009, Hepatology.

Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon-α and the Protease Inhibitors Boceprevir or Telaprevir

J. Lötsch, U. Mihm, E. Herrmann, 2011, Antiviral therapy.

771 DECLINE OF DETECTABLE RESISTANCE MUTATIONS WITHIN THE HCV NS3 PROTEASE QUASISPECIES DURING LONG-TERM FOLLOW-UP AFTER TREATMENT WITH TELAPREVIR

S. Zeuzem, C. Sarrazin, J. Vermehren, 2010 .

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b

X. Tong, R. Ralston, C. Sarrazin, 2012, Journal of viral hepatitis.